Dechert Advises Lysogene on Exclusive License Agreement with Sarepta Therapeutics

Dechert advised Lysogene, a gene therapy company focused on the treatment of orphan diseases of the central nervous system, in its exclusive license agreement with Sarepta Therapeutics, a leader in precision genetics medicines, for a late-stage gene therapy for the treatment of MPS IIIA, a rare inherited neurodegenerative lysosomal storage disorder. The terms of the agreement also include a grant of option rights to an additional central nervous system gene therapy candidate. Payments from Sarepta Therapeutics to Lysogene for all items, if all milestones are met, would total approximately US$125 million plus royalties.

Under the terms of the agreement, Lysogene will be responsible for the completion of the therapy trials and will continue to have exclusive commercial rights to LYS-SAF302 in Europe. Sarepta also made a US$2.5 million equity investment in Lysogene as part of this transaction.  

The cross-border Dechert team was led by New York-based intellectual property partner Thomas Rayski. In Paris, the team consisted of corporate partners Alain Decombe and  Anne-Charlotte Rivière and associates Quentin Durand and Claire Tanguy; antitrust/competition partner Melanie Thill-Tayara and associate Sophie Mitouard; tax partner Bruno Leroy and associate Chahinez Meddeber; and intellectual property national partner Marie Fillon. In the US, the team included antitrust partner Craig Falls and associate Beverly Ang, as well as tax partner Joshua Milgrim and associate Amanda Reed.

Read the French press release »

About Dechert

Dechert is a leading global law firm with 27 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.